GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis

Europe • Euronext Paris • EPA:ALGEN • FR0004053510

2.54 EUR
-0.02 (-0.78%)
Last: Feb 3, 2026, 07:00 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ALGEN. ALGEN was compared to 84 industry peers in the Biotechnology industry. Both the profitability and the financial health of ALGEN get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, ALGEN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year ALGEN was profitable.
  • In the past year ALGEN has reported a negative cash flow from operations.
  • The reported net income has been mixed in the past 5 years: ALGEN reported negative net income in multiple years.
  • In multiple years ALGEN reported negative operating cash flow during the last 5 years.
ALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M

1.2 Ratios

  • ALGEN has a better Return On Assets (3.31%) than 80.95% of its industry peers.
  • ALGEN has a Return On Equity of 7.00%. This is in the better half of the industry: ALGEN outperforms 79.76% of its industry peers.
  • With a decent Return On Invested Capital value of 3.17%, ALGEN is doing good in the industry, outperforming 75.00% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for ALGEN is significantly below the industry average of 11.98%.
Industry RankSector Rank
ROA 3.31%
ROE 7%
ROIC 3.17%
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ALGEN.PA Yearly ROA, ROE, ROICALGEN.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • ALGEN's Profit Margin of 6.14% is fine compared to the rest of the industry. ALGEN outperforms 79.76% of its industry peers.
  • ALGEN has a better Operating Margin (5.97%) than 75.00% of its industry peers.
  • ALGEN has a Gross Margin of 94.91%. This is amongst the best in the industry. ALGEN outperforms 92.86% of its industry peers.
  • ALGEN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 5.97%
PM (TTM) 6.14%
GM 94.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
ALGEN.PA Yearly Profit, Operating, Gross MarginsALGEN.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALGEN is destroying value.
  • ALGEN has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ALGEN has been increased compared to 5 years ago.
  • The debt/assets ratio for ALGEN has been reduced compared to a year ago.
ALGEN.PA Yearly Shares OutstandingALGEN.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALGEN.PA Yearly Total Debt VS Total AssetsALGEN.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • ALGEN has an Altman-Z score of 1.76. This is a bad value and indicates that ALGEN is not financially healthy and even has some risk of bankruptcy.
  • ALGEN has a Altman-Z score of 1.76. This is in the better half of the industry: ALGEN outperforms 69.05% of its industry peers.
  • ALGEN has a Debt/Equity ratio of 0.71. This is a neutral value indicating ALGEN is somewhat dependend on debt financing.
  • The Debt to Equity ratio of ALGEN (0.71) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Altman-Z 1.76
ROIC/WACC0.43
WACC7.32%
ALGEN.PA Yearly LT Debt VS Equity VS FCFALGEN.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M

2.3 Liquidity

  • ALGEN has a Current Ratio of 2.41. This indicates that ALGEN is financially healthy and has no problem in meeting its short term obligations.
  • ALGEN has a Current ratio (2.41) which is comparable to the rest of the industry.
  • ALGEN has a Quick Ratio of 2.21. This indicates that ALGEN is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ALGEN (2.21) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 2.21
ALGEN.PA Yearly Current Assets VS Current LiabilitesALGEN.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

  • ALGEN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.46%.
  • Looking at the last year, ALGEN shows a decrease in Revenue. The Revenue has decreased by -2.21% in the last year.
  • ALGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.46% yearly.
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%

3.2 Future

  • The Earnings Per Share is expected to decrease by 0.00% on average over the next years.
  • The Revenue is expected to grow by 10.37% on average over the next years. This is quite good.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALGEN.PA Yearly Revenue VS EstimatesALGEN.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
ALGEN.PA Yearly EPS VS EstimatesALGEN.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2023 2024 2027 0.05 0.1 0.15 0.2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 16.93, ALGEN is valued correctly.
  • 90.48% of the companies in the same industry are more expensive than ALGEN, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 28.18, ALGEN is valued a bit cheaper.
Industry RankSector Rank
PE 16.93
Fwd PE N/A
ALGEN.PA Price Earnings VS Forward Price EarningsALGEN.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • 90.48% of the companies in the same industry are more expensive than ALGEN, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.51
ALGEN.PA Per share dataALGEN.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y0%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ALGEN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

GENOWAY SA

EPA:ALGEN (2/3/2026, 7:00:00 PM)

2.54

-0.02 (-0.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners7.91%
Ins Owner ChangeN/A
Market Cap24.08M
Revenue(TTM)20.95M
Net Income(TTM)1.29M
Analysts86.67
Price Target6.02 (137.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 16.93
Fwd PE N/A
P/S 1.15
P/FCF N/A
P/OCF N/A
P/B 1.31
P/tB 1.94
EV/EBITDA 8.51
EPS(TTM)0.15
EY5.91%
EPS(NY)0
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS2.21
BVpS1.94
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.56
Profitability
Industry RankSector Rank
ROA 3.31%
ROE 7%
ROCE 3.94%
ROIC 3.17%
ROICexc 3.17%
ROICexgc 3.91%
OM 5.97%
PM (TTM) 6.14%
GM 94.91%
FCFM N/A
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score3
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Debt/EBITDA 2.88
Cap/Depr 297.91%
Cap/Sales 46.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 2.21
Altman-Z 1.76
F-Score3
WACC7.32%
ROIC/WACC0.43
Cap/Depr(3y)64.02%
Cap/Depr(5y)125.45%
Cap/Sales(3y)10.32%
Cap/Sales(5y)17.64%
Profit Quality(3y)100.54%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
EBIT growth 1Y-28.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200%
EBIT Next 3Y68.69%
EBIT Next 5YN/A
FCF growth 1Y-380.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.89%
OCF growth 3YN/A
OCF growth 5YN/A

GENOWAY SA / ALGEN.PA FAQ

Can you provide the ChartMill fundamental rating for GENOWAY SA?

ChartMill assigns a fundamental rating of 4 / 10 to ALGEN.PA.


What is the valuation status of GENOWAY SA (ALGEN.PA) stock?

ChartMill assigns a valuation rating of 2 / 10 to GENOWAY SA (ALGEN.PA). This can be considered as Overvalued.


What is the profitability of ALGEN stock?

GENOWAY SA (ALGEN.PA) has a profitability rating of 5 / 10.


Can you provide the PE and PB ratios for ALGEN stock?

The Price/Earnings (PE) ratio for GENOWAY SA (ALGEN.PA) is 16.93 and the Price/Book (PB) ratio is 1.31.


What is the financial health of GENOWAY SA (ALGEN.PA) stock?

The financial health rating of GENOWAY SA (ALGEN.PA) is 4 / 10.